D&D PharmaTech Co.
D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson's … Read more
Market Cap & Net Worth: D&D PharmaTech Co. (347850)
D&D PharmaTech Co. (KQ:347850) has a market capitalization of $2.48 Billion (₩3.63 Trillion) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #10446 globally and #243 in its home market, demonstrating a 5.83% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying D&D PharmaTech Co.'s stock price ₩83500.00 by its total outstanding shares 43425276 (43.43 Million).
D&D PharmaTech Co. Market Cap History: 2024 to 2026
D&D PharmaTech Co.'s market capitalization history from 2024 to 2026. Data shows growth from $1.44 Billion to $2.48 Billion (55.52% CAGR).
D&D PharmaTech Co. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how D&D PharmaTech Co.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.13x
D&D PharmaTech Co.'s market cap is 0.13 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $1.44 Billion | $11.44 Billion | -$28.62 Billion | 0.13x | N/A |
Competitor Companies of 347850 by Market Capitalization
Companies near D&D PharmaTech Co. in the global market cap rankings as of March 18, 2026.
Key companies related to D&D PharmaTech Co. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
D&D PharmaTech Co. Historical Marketcap From 2024 to 2026
Between 2024 and today, D&D PharmaTech Co.'s market cap moved from $1.44 Billion to $ 2.48 Billion, with a yearly change of 55.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩2.48 Billion | -9.04% |
| 2025 | ₩2.72 Billion | +88.89% |
| 2024 | ₩1.44 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of D&D PharmaTech Co. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.48 Billion USD |
| MoneyControl | $2.48 Billion USD |
| MarketWatch | $2.48 Billion USD |
| marketcap.company | $2.48 Billion USD |
| Reuters | $2.48 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.